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ORIGINAL ARTICLE
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Abstract
Objectives: To explore the personal and/or medical reasons patients on active
surveillance (AS) have, or consider having, further definitive treatment for their
prostate cancer. Research suggests up to 50% of patients on AS will discontinue
within 5 years, though reasons for discontinuation from the patient's perspective is
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under‐explored.
Methods: Prostate cancer patients who were or had been on AS for at least
6 months were recruited. A questionnaire assessed reasons for receiving/considering definitive treatment and the extent to which reasons were personal or medical. Clinical information was extracted from a state‐level population registry. A
subset of participants were interviewed to further explore questionnaire responses.
Results: One‐hundred and‐three individuals completed the survey; 33 were also
interviewed. Fifty‐four survey participants (52%) had discontinued AS for definitive
treatment. Common reasons for discontinuation were evidence of disease progression, doctor recommendation, desire to act, and fear of progression. Many
participants who considered or had treatment reported weighing medical and
personal factors equally in their decision. Interview participants described strongly
considering any amount of disease progression and personal factors such as fear of
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whether to pursue treatment.
Conclusion: Both medical and personal factors are considered when deciding
whether to discontinue AS. Identifying predictors of discontinuation is essential for
informing supportive care services to improve AS management.
KEYWORDS

active surveillance, decision making, mixed methods research, prostate cancer, psycho‐
oncology, qualitative research
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treatment with weak evidence of disease progression) or controls
(patients currently on AS or patients who had transitioned with

Active surveillance (AS) is the recommended best‐available treat-

strong evidence of disease progression), and were matched 1:4. This

ment option for individuals with low risk prostate cancer.1 It involves

resulted in N = 270 eligible participants for recruitment. In the

routine surveillance of biological markers of the disease through

present study, participants were not analysed according to their

prostate specific antigen (PSA) tests, digital rectal examinations, bi-

case/control status. A recruitment flowchart is presented in Figure 1.

1

opsies, and magnetic‐resonance imaging (MRI). Transition to defin-

Eligibility criteria for interviews included: completed survey,

itive treatment (e.g., prostatectomy or radiotherapy) is generally

provided contact information on the returned consent form, had

recommended upon significant disease progression which results in

access to a telephone, and spoke English.

risk reclassification.1 Currently, there is no globally‐recognised criterion of initiation, follow‐up procedures, or triggers for intervention;
therefore, AS practices vary greatly across clinicians and countries.2

2.1.1 | Evidence of disease progression in sample

Approximately 50% of patients discontinue AS within 5 years,
the majority of which with evidence of significant disease progres3,4

Disease progression was determined using the following clinical in-

4–6

formation at diagnosis and follow‐ups: Gleason Score, PSA test re-

the extent to which discontinuation is triggered by disease progres-

sults, and Biopsy results (i.e., positive cores identified). We classified

sion and/or other personal reasons requires further research, espe-

participants into three categories, indicating the level of evidence

cially from the patient perspective. Emerging research suggests this

available indicating significant disease progression had occurred;

sion.

Whilst AS discontinuation rates are commonly reported,

decision may be influenced by both medical (e.g., disease progression,

Strong, Moderate, and Weak. See supplementary material (appendix

doctor recommendation) and personal reasons (e.g., anxiety, pressure

1) for specific criteria.

from family), at least for some people.6–8 For instance, in a cohort
study, Lang et al8 reported that in those who had transitioned from
AS to definitive treatment at 3 years post‐diagnosis, 69% had done so

2.2 | Survey testing, measures and analyses

for medical reasons, 31% for a mix of personal and medical reasons,
and 8% for solely personal reasons. However, this study only illus-

2.2.1 | Survey testing

trated personal reasons as either ‘spousal encouragement’ or ‘unspecified’.8 A more fine‐grained understanding of the personal

Following identification of eligible participants through SA‐PCCOC,

reasons men transition to definitive treatment is needed to assist in

pilot testing on the survey was conducted. The survey underwent

targeting supportive care interventions, thereby encouraging adher-

two separate pilot tests for (a) readability and (b) response rate prior

ence and improved mental wellbeing. In this study, a mixed‐methods

to dissemination of the final version. In the readability pilot, the

approach was used to identify and explore the reasons men discon-

survey was reviewed by four prostate cancer survivors and two

tinue or consider discontinuing AS to receive definitive treatment.

health profressionals, and adjustments were made based on their
feedback. Changes to the study procedure (including the provision of
unconditional monetary incentives to all remaining participants) and

2 | METHODOLOGY

survey length were made given the outcomes of the response rate
pilot test, which was conducted with N = 32 eligible participants.

2.1 | Sample

Following pilot testing, remaining eligible participants (n = 238)
were sent the study materials. Reminder letters were sent to non‐

Participants for this study were sampled from a larger case‐control

responders 2 weeks later. Surveys completed on paper, or the

study designed to examine social‐ecological factors associated with

phone were entered into RedCap,11,12 which also hosted the online

discontinuing AS. Unfortuantely further recruitment from other

version of the survey. Additional clinical data was retrieved from the

Australian states was unable to proceed due to COVID‐19.9 Given

SA‐PCCOC database for participants who completed the survey,

data collection from South Australia had already been completed, the

including demographics and treatment information.

present study reports this cross‐sectional data. Participants were
recruited through the South Australian Prostate Cancer Clinical
Outcomes Collaborative (SA‐PCCOC), which captures 90% of all

2.2.2 | Survey measures

diagnosed prostate cancer survivors in the state.10 SA‐PCCOC
identified patients eligible using the following criteria: diagnosed

The present study examined survey responses on men's reasons for

with prostate cancer between January 2014 and October 2019,

transitioning from AS to definitive treatment, or if still on AS, the

initially monitored through AS for at least six months, 18+ years old,

reasons they had considered having definitive treatment. Fifteen

and had consented to be contacted for research projects through SA‐

items were assessed on a 5‐point Likert scale ranging from 1 (doesn't

PCCOC. As per the original case‐control design, participants were

apply to me) to 5 (strongly applies to me). In analysis, categories were

then identified as either cases (patients identified as transitioning to

collapsed into three categories; Doesn't apply, Minimally/Somewhat

1422
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FIGURE 1

TABLE 1

ET AL.

Participant recruitment flow chart

Reasons for treatment in participants who had undergone definitive treatment after active surveillance (AS)

Reason item

N

Doesn't apply. N (%)

Minimally/Somewhat applies. N (%)

Very much/Strongly applies. N (%)

Mean (SD)

PSA increase

50

2 (4%)

13 (26%)

35 (70%)

4 (1)

Doctor recommendation

48

4 (8.3%)

10 (20.8%)

34 (70.8%)

3.9 (1.2)

Biopsy

46

6 (13.1%)

11 (23.9%)

29 (63%)

3.6 (1.3)

Gleason score increase

45

12 (26.7%)

6 (13.3%)

27 (60%)

3.3 (1.6)

DRE

44

37 (84.1%)

3 (6.8%)

4 (9.1%)

1.4 (1)

Medical comorbidities

43

32 (74.4%)

7 (16.3%)

4 (9.3%)

1.6 (1.2)

Desire to act

47

13 (27.7%)

10 (21.3%)

24 (51.1%)

3.2 (1.6)

Fear of cancer

44

28 (63.6%)

8 (18.2%)

8 (18.2%)

1.9 (1.3)

Pressure from others

46

29 (63%)

10 (21.7%)

7 (15.2%)

1.9 (1.3)

Uncertainty

40

27 (67.5%)

9 (22.5%)

4 (10%)

1.7 (1.1)

Anxiety

45

34 (75.6%)

10 (22.2%)

1 (2.2%)

1.4 (0.8)

Tired of waiting

42

33 (78.6%)

7 (16.7%)

2 (4.8%)

1.4 (0.9)

Inconvenient protocol

43

39 (90.7%)

4 (9.3%)

0 (0%)

1.1 (0.4)

Depression

43

39 (90.7%)

4 (9.3%)

0 (0%)

1.1 (0.5)

Medical reasons

Personal reasons

applies, and Very‐much/Strongly applies. See Table 1 for all items.

needs, their relationship with doctors, and their experiences on AS.

The main reason for treatment/considering treatment was also

Findings related to these measures will be reported elsewhere.

assessed on a visual analogue scale (VAS), where zero indicated
purely personal reasons and 100 indicated purely medical/clinical
reasons. These items were informed by previous literature7,13 and

2.2.3 | Survey analyses

purpose‐written by the research team (see supplementary material
appendix 2). The full survey also included validated measures and

Descriptive statistics for demographics, considering treatment, rea-

purpose‐written questions on demographics, anxiety, depression,

sons for undergoing definitive treatment, and main reason for un-

coping strategies, physical activity, social support, supportive care

dergoing treatment were calculated in R.14
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discontinued AS, 11 had strong evidence of progression, 19 moderate evidence, and 23 weak evidence of progression. Two par-

Participants were sampled using Criterion‐I purposeful sampling

ticipants reported on the survey they had ceased all treatments

technique. This involves identifying and selection participants ac-

and were not attending any follow‐up for their cancer, however

cording to predetermined criterion of importance, which enables

both participants received a repeat biopsy. Approximinately 61%

researchers

of participants received a repeat biopsy an average of 17 months

to

deepen

the

understanding

of

results

from

information‐rich cases.15 Participants with VAS scores under 70,

after diagnosis.

had considered leaving AS, were located in outer regional/remote

The average time on AS was 2.1 years (SD = 1.3) for those who

areas, and had reported higher scores of anxiety, depression, and

had since undergone treatment, and 3.3 years (SD = 1.1) for those

unmet supportive care needs were prioritised for interview selec-

currently on AS. Thirty percent of those currently on AS (n = 14)

tion. All participants were interviewed by lead author Megan

reported that they had considered discontinuing to have definitive

McIntosh (MMh; who had prior qualitative research experience).

treatment. The average time for those currently on AS who had

Interviews were semi‐structured, and followed a topic guide (see

considered leaving was 4 years (SD = 0.9), versus 4.3 years (SD = 0.9)

supplementary material appendix 3) which explored experiences on

for those who had not considered discontinuing.

AS, reasons for treatment or considering treatment, and treatment
experiences. Interviews were audio recorded and transcribed
verbatim, taking an average 31 min to complete. Braun and Clarke

3.2 | Reasons for leaving active surveillance

have recommended thematic saturation should not be the primary
aim of sample size calculations and recruitment when conducting

The most common reasons participants who went onto have defini-

thematic analysis.16 Rather, all participants who met elibility and

tive treatment endorsed to have very much or strongly influenced

sampling criteria were invited to ensure richness of data to address

their decision included a rise in PSA level (70%), receiving a doctor's

the research questions.

recommendation to have further treatment (60%), a change in
Gleason score (63%) or change in repeat biopsy results (70%),
experienced fear of cancer progression (18%), or had a strong desire

2.3.1 | Interview analysis

to do something to cure the cancer (51%). Few people reported
comorbidities or anxiety strongly influenced their decision. See

Transcripts were analysed using Braun and Clarke's reflexive
16,17

thematic analysis method.

Table 1 for a complete overview.

This involves six key steps: Famil-

Tables were produced to examine the reasons for leaving AS

iarisation, Coding, Create Themes, Revise Themes, Define Themes,

by level of disease progression evidence (strong, weak moderate;

Writing. The Familiarisation and Coding steps were performed by

see supplementary material appendix 4). In brief, average scores

MM and Melissa J Opozda (MJO), who both have experience in

endorsing medical reasons were marginally higher among those

qualitative research and thematic analysis. All transcripts were

with highest levels of evidence for disease progression. Similarly,

then re‐analysed by MM and themes were created. MM and MJO

participants with weaker evidence for progression more strongly

then revised and formally defined the themes, and a thematic map

endorsed

was created to illustrate the relationship between themes. Themes

marginal.

personal

reasons,

though

again

differences

were

and the thematic map were reviewed and finalised by all authors.
Results were written with transcript excerpts to illustrate the
findings.

3.3 | Balance of medical and personal reasons
impacting decision making

3 | RESULTS

Figure 2 displays the VAS scores for people who discontinued AS
to undergo definitive treatment (N = 44, 10 missing) and those

3.1 | Participants

who have considered ceasing AS for definitive treatment (N = 11,
3 missing). The majority of participants reported both personal and

One hundred and three participants completed the survey and con-

medical reasons influenced decision making, but to varying de-

sent form (38% response rate). The average participant was married

grees. Among those who had received treatment, almost half had a

(83%), retired (64%), had completed post‐secondary education (70%),

VAS indicating their main reason for AS discontinuation was

and lived in an Australian state capital city (71%). See Table 2 for

medically and personally balanced (i.e., VAS score of 50) or was

complete breakdown of demographics.

tipped towards personal (i.e., VAS of 0–50). Another third had a

Of the 103 participants, 53 (51%) participants had dis-

VAS score indicating reasons were predominantly medical (i.e., VAS

continued AS and since undergone definitive treatment, and 48

score of 90+). In participants still on AS, many indicated their

(47%) participants were currently on AS. In patients who had

desire for treatment was medically and personally balanced (VAS

1424
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Participant demographics and clinical information
All participants (n = 103)

Treatment (n = 53)

Active surveillance (n = 48)

Age at diagnosis: Mean (SD)

64.5 (6.6)

63.7 (7.1)

65.4 (5.6)

Age at diagnosis range: years

48–75

48–75

49–74

Time on active surveillance: Mean years (SD)

2.5 (1.4)

2 (1.2)

3.2 (1.1)

53 (51.4%)

‐

‐

48 (46.6%)

‐

‐

2 (1.9%)

‐

‐

Prostatectomy

‐

33 (62.3%)

‐

Radiation

‐

23 (43.4%)

‐

Other (e.g., Hormone Therapy)

‐

2 (3.8%)

‐

Single

3 (2.9%)

3 (5.7%)

0

Married/De facto/Partnered

86 (83.5%)

42 (79.2%)

43 (89.6%)

Divorced/Separated

9 (8.7%)

5 (9.4%)

3 (6.3%)

Widowed

5 (4.9%)

3 (5.7%)

2 (4.2%)

Working (full or part time)

32 (31%)

14 (26.4%)

17 (35.4%)

Retired

66 (64.1%)

35 (66%)

30 (62.5%)

Unemployed

5 (4.9%)

4 (7.6%)

1 (2.1%)

Primary

3 (2.9%)

0

3 (6.3%)

Secondary

27 (26.2%)

16 (30.2%)

11 (22.9%)

Vocational Training/Education

36 (35%)

16 (30.2%)

18 (37.5%)

University

37 (35.9%)

21 (39.6%)

16 (33.3%)

Remote

5 (4.9%)

2 (3.7%)

3 (6.4%)

Outer regional

11 (10.7%)

6 (11.1%)

4 (8.5%)

Inner regional

14 (13.6%)

4 (7.4%)

9 (19.1%)

Major city

73 (70.9%)

42 (77.8%)

31 (66%)

Transperineal

21 (20.4%)

12 (22.6%)

8 (16.7%)

Transrectal Ultrasound (guided)

30 (29.1%)

15 (28.3%)

14 (29.2%)

Transurethral resection of prostate

12 (11.7%)

3 (5.7%)

9 (18.8%)

Current treatment status: N (%)
Had treatment
On active surveillance
Ceased all treatment with no follow‐up care

a

b

Treatment type: N (%)

Marital status: N (%)

Employment: N (%)

Education: N (%)

c

Location : N (%)

Diagnostic biopsy type: N (%)

40 (38.8%)

23 (43.4%)

16 (33.3%)

Received repeat biopsy: N (%)

Not reported

63 (61.2%)

30 (56.6%)

31 (64.6%)

Time between diagnostic and repeat biopsy: Mean months (SD)

17.4 (12.7)

18.5 (12.2)

16.5 (13.6)

Transperineal

36 (57.1%)

17 (56.7%)

18 (58.1%)

Transrectal Ultrasound (guided)

21 (33.3%)

9 (30%)

12 (38.7%)

Transurethral resection of prostate

4 (6.4%)

3 (10%)

1 (3.2%)

Repeat biopsy type: N (%)

MCINTOSH
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T A B L E 2 (Continued)
All participants (n = 103)

Treatment (n = 53)

Active surveillance (n = 48)

Not reported

2 (3.2%)

1 (3.3%)

0

MRI conducted (prior/post diagnosis): N (%)

68 (66%)

39 (73.6%)

27 (56.3%)

a

The two participants who reported they ‘ceased all treatment with no follow‐up care’ were not grouped into the AS or treatment categories, though
their demographics have been included in the total sample.

b

Some participants received more than one treatment, therefore the percentage does not equal 100.

c

Location determined by postcodes and classified using the Australian Statistical Geographical Classification – Remoteness Area framework.27

FIGURE 2

Visual analogue scale (VAS) scores reflecting reasons for having/wanting definitive treatment in participants

score of 50), or trended towards predominantly medical reasons

retired (61%), educated beyond high school (79%), and lived in a

(VAS scores of 75+).

major city (64%).

When analysed by disease progression (in participants who had
discontinued AS), average VAS scores were generally higher in the
‘Strong’ progression group (M = 72.8, SD = 22.1) versus the Mod-

3.5 | Overview of themes

erate (M = 65.6, SD = 25.7) and Weak (M = 69, SD = 30.6) groups.
Men discussed a wide range of reasons they considered or had
transitioned off AS to have definitive treatment. Ultimately, most

3.4 | Qualitative sample

participants were primarily motivated by medical reasons, though
their decision was significantly supported or influenced by per-

Thirty‐three participants were interviewed. Of these, 10 (30.3%)

sonal reasons. We identified three major themes: “Disease pro-

were still on AS at the time of the interview (although one had a

gression indicates need for action”, “A desire to act now”, and

prostatectomy upcoming). The remaining 23 interviewees (69.7%)

“Fear, worry, and uncertainty”. We did not note any major dif-

had left AS and had undergone definitive treatment for their

ferences in themes between patients' post‐treatment and those

prostate cancer. Most interview participants were married (82%),

still

on

AS,

and

as

such

results

are

reported

together.

1426
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Thematic map of themes

Participants' reasons for treatment are illustrated in a thematic

least to take [Dr M's] advice to explore what surgery

map (see Figure 3), with the larger ovals depicting reasons more

options are open to me.” P15132, Prostatectomy.

often discussed by participants, and the smaller ovals reflecting
reasons less commonly discussed.

3.5.2 | A desire to act now
3.5.1 | Disease progression indicates need for
treatment
“Well, I mean, cancer is not good in your body, and it
By far the most common reason participants stated they had or

can spread. So I think the sooner you get rid of it, the

considered having treatment was because their doctor made the

better. That's my opinion.” P14774, Active Surveillance

recommendation to do so. Some participants noted they sought

but scheduled for Prostatectomy.

advice from several doctors before making the decision to transition
from AS to treatment.

Several participants expressed a clear and intense desire to
seek definitive treatments as soon as possible after diagnosis. For

“I did toy with the idea, you know, should I wait

some, this was not offered or recommended at diagnosis and pa-

another 12 months. And he advised it wouldn't be a

tients were advised to wait until the cancer had progressed

good idea” P16058, Prostatectomy

further. In other circumstances, although progression was detected
doctors advised participants that they could remain on AS. How-

Participants also explained that any disease progression identi-

ever, some participants viewed the doctor's mention of progression

fied from PSA, Gleason, MRI, or biopsy results often prompted them

and having provided the option to undergo treatment as a reason

to discuss treatment options with their doctor. In almost all cases,

to have definitive treatment and felt staying on AS would be risky.

participants considered any level of progression to be the first reason

Despite being eligible for AS, participants often felt that having

they considered and underwent definitive treatments. Men on AS

definitive treatments would provide more control over outcomes

said they would seek definitive treatments if or when tests indicated

and were fearful that the cancer would progress outside the

the cancer had progressed, irrespective of if this level consitituted

prostate.

disease reclassification.
“This why I was pushing the doctor to do something like
“I've gone from having a low PSA to quite a high PSA,

surgery. But before then it was just too small. He went

my PSA started fluctuating… So there was obviously

active surveillance. For me, I was always pushing, no no, I

something happening… When we got to the serious

don’t want that. Remove it please.” P9160, Prostatec-

decision‐making stage… I'm thinking, you know, at

tomy, Radiation, and Hormone Therapy.

MCINTOSH
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Some participants who had been on AS for several years

treatment as soon as possible. Delaying treatment by remaining on

expressed that their decision to have treatment was also influ-

AS in such cases was viewed as riskier than having treatment and

enced by the nature of AS follow‐up. The regular tests, particularly

avoiding the consequences that they had heard others had

annual biopsies, and mental load of continuing to watch for dis-

experienced.

ease progression, became tiring and inconvenient for participants
over time.

“Keeping in mind though, that an old friend of mine got
prostate cancer at about the same age as I did and said

“I almost got tired, I guess. I guess of having nine years

‘oh nah, I'm not worried about it. You die with it rather

of just sitting there wondering what's going on.

than from it’. But eight years later, he was dead from it.

Mentally I was just done.” P15132, Prostatectomy.

So I've always had in the back of my mind. You know,
keep an eye on it. What I'm trying to say, I think it's

Several patients also mentioned that their decision to transition

been, It's been at the back of my mind and a little bit

off AS and pursue definitive treatment was influenced by the state of

concerning” P15005, Active surveillance but scheduled

their current health, such as their age, fitness, and life expectancy.

for Prostatectomy.

Participants felt that seizing the opportunity to have treatment while
they were still ‘young and healthy’ would assist their recovery.

Participants also explained they chose to have treatment often
because they wanted to ensure they would continue to be around for

“And it, ah, occurred to me that if I was going to do

their family, and that having definitive treatment would reduce their

anything, I might as well do it now. While I’m still

family's worry.

reasonably active and so forth, and could recover, I
would hope. Without too much difficulty.” P10433,
Brachytherapy.

“During that period, it was horrible, you know, I was a
little bit depressed you know, knowing that I'd been
diagnosed with this. And we have a big family, my
children are still young. How am I meant to leave them
if I die, earlier like this?” P9160, Prostatectomy, Radi-

3.5.3 | Fear, worry, and uncertainty

ation, and Hormone Therapy.

Participants often reported ongoing fears that the cancer would
progress undetected, and they could be at risk of metastases or
dying. It was common for participants to fear that delaying treatment

4 | DISCUSSION

was risky, as their PSA test might increase suddenly and it would be
‘too late’ to treat or cure the cancer. Ongoing anxiety or concerns

This study investigated the reasons people transition, or consider

that progression would occur too quickly were common reasons why

transitioning, from AS to definitive treatments. Results indicate that

participant sought or had considered treatment.

the reasons patients decide to leave AS are more complex than the
literature often suggests.

“I thought, my wife and I discussed it quite a lot… she

Previous literature reporting rates of AS discontinuation often

was really concerned. And I guess I was concerned as

categorise participants according to progression criteria available

well a little bit that, yeah it was internal, which was

on cancer registries,4,6 and have rarely explored participants' own

okay, so it was contained within the prostate, but there

perspectives of reasons for discontinuation, nor considered the

was always that fear… if it does get out and gets into

extent to which personal reasons influence those with evidence of

your system elsewhere, I knew it could take off pretty

disease progression. This may actually hinder health professionals

quickly. And then you're, you know, you're fighting a

from providing support to patients questioning when to transition

bigger battle. It's probably best to get it done before it

to definitive treatment. Our results suggest that patients on AS

goes.” P14835, Prostatectomy.

often consider a variety of medical and personal factors when
deciding whether to continue on AS or undergo definitive treat-

Participants also discussed the influence that other people's

ment, regardless of strength of evidence for disease progression.

experiences with prostate cancer had on their desire for treat-

Evidence of disease progression, regardless of whether it meets

ment. Negative vicarious experiences of prostate cancer and

criteria for disease reclassification, is considered strongly by men

hearing ‘horror stories’, whether directly from friends or family or

as a reason to pursue definitive treatment. In addition, we found

indirectly online or via the media, was described as a reason

patients may still consider and pursue treatment irrespective of

participants had experienced fears of progression and desired

whether the doctor states such progression warrants intervention.
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Participants in this study described feeling anxious when any

clinical factors and personal factors are strongly considered by

evidence of cancer progression was detected. Cancer progression,

patients during this process. Identifying predictors of discontinuing

or the fear of it, prompted participants to consider their future

AS with and without evidence of disease progression or risk

and the impact that delaying definitive treatment could have on

reclassification may further assist health professionals in targeting

their own health and their family. Fear of cancer recurrence is a

patients for support during the first few years on AS, when

significant issue for people with a cancer history, and several

emotional distress and discontinuation rates are higher. Lessons

18,19

successful interventions have been developed.

Lessons from

from interventions targeting fear of cancer recurrence may be

this literature may be useful to address fear of cancer progres-

useful for guiding the development of supportive care interventions

sion in this population, whilst dispelling common misconceptions

to address fear of cancer progression in this population. However,

regarding prostate cancer and treatment (e.g., prostate cancer

additional strategies to target other personal reasons, such as

progresses rapidly) and promoting positive vicarious experiences

family pressure and negative vicarious experiences, are also ex-

of AS.

pected to be useful.

Several of the personal reasons, such as fear of progression and
family pressure, have been identified in previous research.7,8,13

A U T H O R C O N T R I B U T I O NS

Significant research has reported low levels of anxiety in men on

All authors contributed to the study conception and design. Ma-

AS, which often reduces or remains stable over time.20–23 However,

terial preparation, data collection, analysis, and the manuscript

much of this research recruited patients from cancer centres which

draft was primarily performed by Megan McIntosh. Remaining

specialise in AS, which may have resulted in improved AS man-

authors provided critical feedback and assistance through all

agement and greater acceptance from both patients and doctors.

stages of the study (material preparation, data collection, analysis,

Recent research conducted with patients from non‐specialist AS

and manuscript drafts). All authors read and approved the final

cancer centres have found men on AS experience more fear of

manuscript.

cancer progression and generalised anxiety (immediately and long‐
term) than those who have definitive treatment.24,25 Further

A CK NO W L E DG E M E NT S

research is required to provide a more representative understand-

We would like to extend our gratitude to the prostate cancer sur-

ing of distress in AS patients, with consideration of crucial time‐

vivors who participated in this study. We would also like to thank the

points (for example, prior to treatment choice and follow‐up

team at SA‐PCCOC for assisting in recruitment and data collection.

appointments.
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4.1 | Study limitations
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from well as the Freemasons Centre for Male Health and Wellbeing.

Despite our novel findings, the limitations must be considered. The

Open access publishing facilitated by The University of Mel-

original case‐control study, which was paused due to COVID‐19,

bourne, as part of the Wiley ‐ The University of Melbourne agree-

planned to recruit from multiple Australian states. The intended

ment via the Council of Australian University Librarians.

larger sample size would have enabled investigation into predictors
of AS discontinuation. Despite this, we were able to recruit 103
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participants into the study and collected both quantitative and
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qualitative data. In addition, the registry does not collect data on
education or marital status, and the representativeness of our sample

CONSENT TO PARTICIPATE & PUBLISH

in regard to the registry population was difficult to determine.

Informed consent was obtained from all individual participants. All

However, our sample is similar to the registry population in terms of

authors confirm that all participants provided informed consent for

age and location.26 Finally, our study did not recruit participants

their de‐identified data to be included in this manuscript.

whose primary language was not English, therefore results may not
be generalisable to patients from culturally and linguistically diverse
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backgrounds.

Data will be made available on Figshare. Please contact the corresponding author.

4.2 | Conclusion & clinical implications
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